Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company PIC

Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out‑Licensing Deal Marked

Fineline Cube Aug 27, 2026
Company PIC

HitGen Posts 52% Revenue Growth in 1H 2026 as DEL Segment Surges 62% and Recurring Profit Jumps 43%

Fineline Cube Aug 27, 2026
Company PIC

Junshi Biosciences Achieves First‑Ever Semiannual Profitability as Toripalimab Sales Surge 36%

Fineline Cube Aug 27, 2026
Company Drug PIC

FDA Approves Revolution Medicines’ Rasonque (daraxonrasib), an Oral Multi‑Selective RAS(ON) Inhibitor, for Metastatic Pancreatic Cancer

Fineline Cube Aug 27, 2026
Company Drug PIC

NMPA Approves Novartis’ Pluvicto Plus ARPI for PSMA‑Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer

Fineline Cube Aug 26, 2026
Company PIC

Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out‑Licensing Deal Marked

Fineline Cube Aug 27, 2026
Company PIC

Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out‑Licensing Deal Marked

Fineline Cube Aug 27, 2026
Company PIC

HitGen Posts 52% Revenue Growth in 1H 2026 as DEL Segment Surges 62% and Recurring Profit Jumps 43%

Fineline Cube Aug 27, 2026
Company Medical Device

Sino Medical Sciences Gains Mexican Approval for Coronary Balloon Catheters

Fineline Cube May 12, 2025

China-based Sino Medical Sciences Technology Inc. (SHA: 688108) announced that it has received marketing approval...

Company Drug

Abogen’s ABO2102 mRNA Cancer Vaccine Gets US Clinical Trial Approval

Fineline Cube May 9, 2025

China’s Abogen Biosciences Co., Ltd, a developer of messenger ribonucleic acid (mRNA) drugs, announced that...

Company Drug

J&J’s Tremfya Approved for Ulcerative Colitis in China

Fineline Cube May 9, 2025

US giant Johnson & Johnson (J&J, NYSE: JNJ) announced that it has received marketing approval...

Policy / Regulatory

China’s CDE Reveals 93rd Batch of Reference Preparations for GQCE

Fineline Cube May 9, 2025

China’s Center for Drug Evaluation (CDE) has released the 93rd batch of reference preparations for...

Policy / Regulatory

NHC Issues Guidelines for Geriatric Medicine Departments Construction and Management

Fineline Cube May 9, 2025

The National Health Commission (NHC) this week released the “Guidelines for the Construction and Management...

Company

Takeda Reports 2.8% Revenue Growth in Fiscal 2024, Driven by Product Sales

Fineline Cube May 9, 2025

Japan-headquartered Takeda (NYSE: TAK, TYO: 4502) released its financial report for fiscal year 2024 (April...

Company

Zai Lab Reports Q1 2025 Revenue Growth and Pipeline Progress

Fineline Cube May 9, 2025

China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) released its Q1 2025 financial report...

Company Drug

Shanghai BDgene’s BD111 Gene Therapy Advances to Phase II Clinical Trials

Fineline Cube May 9, 2025

Gene therapy specialist Shanghai BDgene Technology Co., Ltd has advanced its BD111 pipeline candidate into...

Company Deals Hospital

Prudential Hong Kong Collaborates with Foshan Fosun Chancheng Hospital for Direct Payment Services

Fineline Cube May 9, 2025

Prudential Hong Kong Limited, a subsidiary of UK-based Prudential plc, has entered into a strategic...

Company Deals

Sanyou Medical Partners with CGBio to Launch Regenerative Medicine Joint Venture

Fineline Cube May 9, 2025

China-based Shanghai Sanyou Medical Co., Ltd (SHA: 688085) announced plans to establish a joint venture...

Company Drug

Hengrui Pharma Files for New Dalpiciclib Indication in Early Breast Cancer

Fineline Cube May 9, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that a new indication approval filing...

Company Deals

Gilead Sciences Announces $11 Billion Investment in US Expansion

Fineline Cube May 9, 2025

US-based major Gilead Sciences Inc. (NASDAQ: GILD) announced an additional investment of USD 11 billion...

Company Drug

Humanwell Healthcare Gains NMPA Approval for Giapreza Generic in Shock Therapy

Fineline Cube May 9, 2025

China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced that it has received clinical trial...

Company Drug

Humanwell Healthcare Gains NMPA Clearance for HZ-J001 Cream in Vitiligo Trial

Fineline Cube May 9, 2025

China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced that it has received clearance from...

Company Deals

Pfizer Partners with HSITP to Boost Life Sciences Innovation in Greater Bay Area

Fineline Cube May 9, 2025

US giant Pfizer Inc. (NYSE: PFE) has entered into a partnership with Hong Kong-Shenzhen Innovation...

Company Deals

Insilico Medicine Files for IPO to Leverage AI in Drug Discovery

Fineline Cube May 9, 2025

China-based Insilico Medicine, a biotech company leveraging generative artificial intelligence (AI), has filed for an...

Company Drug

Pfizer’s Zavicefta Approved by China’s NMPA for Severe Infections in All Ages

Fineline Cube May 9, 2025

US-based pharmaceutical giant Pfizer (NYSE: PFE) announced that it has received market approval from China’s...

Company Drug

Amgen’s Tepezza Approved in UK for Thyroid Eye Disease Treatment

Fineline Cube May 9, 2025

US biotech Amgen (NASDAQ: AMGN) announced that the UK’s Medicines and Healthcare products Regulatory Agency...

Company Deals

Guangzhou Regenverse Therapeutics Raises RMB 100 Million in Pre-Series A Financing

Fineline Cube May 8, 2025

China-based Guangzhou Regenverse Therapeutics Co., Ltd (former name: Guangzhou Regen Therapeutics Co., Ltd.), a developer...

Company

Novo Nordisk Reports 18% YOY Revenue Growth in Q1 2025

Fineline Cube May 8, 2025

Denmark-based Novo Nordisk (NYSE: NVO, CPH: NOVO-B) released its Q1 2025 earnings report this week....

Posts pagination

1 … 212 213 214 … 713

Recent updates

  • Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out‑Licensing Deal Marked
  • HitGen Posts 52% Revenue Growth in 1H 2026 as DEL Segment Surges 62% and Recurring Profit Jumps 43%
  • CSPC’s PD-1/IL-15 Bispecific SYS6090 (JMT108) Granted FDA Fast Track for MSS/pMMR Metastatic Colorectal Cancer
  • Insilico Medicine Swings to Profitability as Revenue Surges 287% in 1H 2026, Rentosertib Advances to Phase 3
  • Huadong Medicine’s ROR1 ADC HDM2005 Granted FDA Fast Track Designation — First Domestic ROR1 ADC to Achieve the Status
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company PIC

Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out‑Licensing Deal Marked

Company PIC

HitGen Posts 52% Revenue Growth in 1H 2026 as DEL Segment Surges 62% and Recurring Profit Jumps 43%

Company Drug

CSPC’s PD-1/IL-15 Bispecific SYS6090 (JMT108) Granted FDA Fast Track for MSS/pMMR Metastatic Colorectal Cancer

Company

Insilico Medicine Swings to Profitability as Revenue Surges 287% in 1H 2026, Rentosertib Advances to Phase 3

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.